moxifloxacin has been researched along with ag-1549 in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ag-1549) | Trials (ag-1549) | Recent Studies (post-2010) (ag-1549) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 31 | 3 | 1 |
| Protein | Taxonomy | moxifloxacin (IC50) | ag-1549 (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.0587 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.0587 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amantea, MA; Nickens, DJ; Raber, SR; Reynolds, RR; Sarapa, N | 1 |
1 trial(s) available for moxifloxacin and ag-1549
| Article | Year |
|---|---|
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Topics: Adult; Aza Compounds; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drug Therapy, Combination; Electrocardiography; Female; Fluoroquinolones; Heart Rate; HIV Protease Inhibitors; Humans; Imidazoles; Ketoconazole; Liver; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Reference Values; Reproducibility of Results; Research Design; Reverse Transcriptase Inhibitors; Ritonavir; Sulfur Compounds; Treatment Outcome | 2008 |